Delpacibart is a monoclonal antibody categorized as a bispecific T-cell engager (BiTE) designed to treat relapsed or refractory multiple myeloma by simultaneously binding CD3 on T cells and BCMA on malignant… Read more
Delpacibart is a monoclonal antibody categorized as a bispecific T-cell engager (BiTE) designed to treat relapsed or refractory multiple myeloma by simultaneously binding CD3 on T cells and BCMA on malignant plasma cells. This targeted mechanism drives T-cell mediated cytotoxicity to eliminate cancer cells. Laboratories working with this therapeutic require high-quality reference standards to ensure rigorous pharmaceutical development and manufacturing. Related compounds, including impurities, degradation products, and stable isotope-labeled standards, are essential for analytical testing and comprehensive impurity profiling. These tools allow researchers to perform accurate method validation and maintain strict quality control standards throughout the drug development lifecycle. By utilizing these precise analytical materials, scientists can effectively monitor stability and ensure consistency, providing reliable data for regulatory compliance and safety assessments in the biopharmaceutical industry.